Background
Single-institution retrospective study (University of Michigan) evaluating clinical and histopathological features of primary MCC that predict sentinel lymph node (SLN) positivity. 95 patients with MCC who underwent SLN biopsy (93 successful SLN identifications). Analyzed: tumor size, thickness, mitotic rate, histologic growth pattern (nodular vs. infiltrative).
Interventions and follow up
Arm A: MCC with SLN biopsy — single-arm analysis; no interventio
Arm B: N/A
Primary endpoint: Predictors of SLN positivity
mFollow up: N/A (staging study)
Arm B: N/A
Primary endpoint: Predictors of SLN positivity
mFollow up: N/A (staging study)
Results
SLN positivity rate: ~30–35% overall
Significant predictors of SLN+: Larger clinical size; greater histologic dimension; increased tumor thickness; higher mitotic rate; infiltrative growth pattern
Multivariate models: Infiltrative pattern + tumor thickness OR infiltrative pattern + mitotic rate — both models significant
Key finding: No subgroup predicted <15–20% likelihood of SLN positivity → SNB recommended for all clinical N0 MCC
Significant predictors of SLN+: Larger clinical size; greater histologic dimension; increased tumor thickness; higher mitotic rate; infiltrative growth pattern
Multivariate models: Infiltrative pattern + tumor thickness OR infiltrative pattern + mitotic rate — both models significant
Key finding: No subgroup predicted <15–20% likelihood of SLN positivity → SNB recommended for all clinical N0 MCC
Adverse events
Main adverse events: SLN biopsy: standard surgical morbidity (hematoma, infection, sensory changes). No treatment intervention in this staging study.
Conclusions
All clinicopathologic features of MCC tested were associated with increased likelihood of SLN positivity, and no low-risk subgroup had <15–20% SLN positivity. This provides the evidence base for recommending SLN biopsy in all patients with MCC without clinically evident nodal disease, to guide adjuvant treatment (RT or observation for SLN-negative).
Key Limitations
Key Limitations: Single institution; retrospective case series; SLN technique variability; does not address impact of SLN status on survival outcomes; Merkel cell polyomavirus (MCPyV) status not incorporated as biomarker; pre-immunotherapy staging era.
Clinical Context
Establishes the rationale for universal SLN biopsy in MCC. Current NCCN guidelines recommend SLN biopsy for all MCC T1–T4 N0 M0 (unless contraindicated). SLN status determines adjuvant RT field (regional nodes vs. primary site only) and prognosis. MCPyV-negative MCC has worse prognosis and higher metastatic potential.
References